Recombinant CD22 (Epratuzumab Biosimilar) antibody

Catalog No. ABIN7795107

The Humanized Monoclonal anti-CD22 (Epratuzumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect CD22 (Epratuzumab Biosimilar) in samples from Human.

Quick Overview for Recombinant CD22 (Epratuzumab Biosimilar) antibody (ABIN7795107)

Target: CD22 (Epratuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD22 (Epratuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Epratuzumab Biosimilar, CD22 Monoclonal Antibody

Characteristics: Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab. Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD22

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD22 (Epratuzumab Biosimilar)

Target: CD22 (Epratuzumab Biosimilar)

Alternative Name: Epratuzumab Biosimilar

Target Type: Biosimilar